louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02610972: Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Case-control Study
Official title: Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Case-control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Preeclampsia
Keywords: Congo Red test GV-005
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
Collaborators: name: International Centre for Diarrhoeal Disease Research, Bangladesh
First posted: 2015-11-20
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women attending Dhaka Medical College (Dhaka) with clinically confirmed cases of preeclampsia and clinically healthy women who deliver at term will be eligible for the study.

Brief summary: A case-control study will evaluate the clinical utility of the Congo Red test GV-005 in following women with a clinical diagnosis of preeclampsia and clinically healthy women in the postpartum period

Detailed description: A case-control study (n=150) will evaluate the clinical utility of the Congo Red test GV-005 in following women with a clinical diagnosis of preeclampsia and clinically healthy women in the postpartum period. Women with preeclampsia (n=100) (cases) and clinically healthy women (n=50)(controls) who are hospitalized postpartum will be recruited for the trial. All women will be asked to provide a urine sample. Samples will be collected daily during a woman's hospitalization. The Congo Red test GV-005 and a standard urine dipstick proteinuria test will be performed by a lab technician within 72 hours of sample collection. The purpose of this research is to evaluate progression of urine congophilia postpartum by following patients diagnosed with preeclampsia and clinically healthy women.

Eligibility criteria: Inclusion Criteria:

* Postpartum
* Clinical diagnosis of preeclampsia (severe, mild or superimposed) including eclampsia (n=100) OR Clinically healthy (n=50)
* Eligible to consent for research
* Agree to comply with study procedures
* Able to give informed consent

Exclusion Criteria:

* None

Primary outcomes:
measure: Prevalence of Urine Congophilia Using Congo Red Test GV-005
timeFrame: within 72 hours of urine sample collection
Secondary outcomes:
Other outcomes:
Locations:
city: Dhaka
country: Bangladesh
facility: Dhaka Medical College
city: Mexico City
country: Mexico
facility: Hospital Materno-Infantil Inguarán
Study officials:
affiliation: Gynuity Health Projects
name: Beverly Winikoff, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05912972: Development and Management of Registry in Patients With Gynecologic Cancer in Korea
Official title: Development and Management of Registry in Patients With Gynecologic Cancer in Korea
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2023-06-22
Enrollment: 13500
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with gynecologic cancer undergoing treatment

Brief summary: The goal of this observational study is to identify and analyze the characteristics, treatment trends, prognostic factors and survival prognosis of Korean gynecologic cancer patients. Ultimately, the final goal is to contribute to the development of safe surgical methods and treatment for gynecologic cancer to improve survival rates.

Detailed description: Cervical cancer, endometrial cancer, and ovarian cancer represent gynecologic cancers. There are many open issues that need to be addressed, specifically the surgical method, disease recurrence and survival outcome in the so called "real world" setting. The aim of this observational study is to collect both retrospective and prospective medical information of gynecologic cancer patients.

Eligibility criteria: Inclusion Criteria:

* Female patients 18 years or older
* Written informed consent (prospective cohort)
* Confirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Exclusion Criteria:

* Unconfirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Primary outcomes:
measure: Overall survival
timeFrame: 5 years
Secondary outcomes:
measure: Progression-free survival
timeFrame: 5 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Jeong-Yeol Park, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02965872: Learning Effect of Computerized Balance Evaluation System
Official title: Investigating the Learning Effect of Computerized Balance Evaluation System
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Healthy
Keywords: Postural Balance
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2016-11-17
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy individuals

Brief summary: Thirty healthy individuals will be participants of the study. Participants will evaluate with the following assessment tools: Demographic datas; age, gender, height, body mass, will be recorded. Postural sway and limits of stability parameters will evaluate with computerized balance evaluation system (BERTEC) for seven times .

Detailed description: Thirty healthy individuals will be participants of the study. Participants will evaluate with the following assessment tools: Demographic datas; age, gender, height, body mass, will be recorded. Postural sway and limits of stability parameters will evaluate with computerized balance evaluation system (BERTEC) for seven times. Every seven evaluations will be repeated while participants in combination of the condition including eyes open, eyes closed, normal surface and perturbated surface.

Eligibility criteria: Inclusion Criteria:

* Want to participate

Exclusion Criteria:

* Have passive joint limitation at extremities
* Surgery at last 5 year
* Systemic problems such as neurologic disorders, rheumatoid disorders...
* Another orthopedic anomalies

Primary outcomes:
measure: Balance evaluation
timeFrame: Initially evaluation at first minute,5 minutes(mns) after the initially evaluation, 10 mns after initially evaluation,15 mns after initially evaluation,20 mns after initially evaluation,25 mns after initially evaluation,30 mns after initially evaluation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02425072: NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
Official title: NovoTTFTM-100A System Therapy for Refractory CNS Involved Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Small Cell Lung Cancer
Brain Metastasis
Keywords: Cancer
Brain
Lung
Small-cell
Lead sponsor: University of Kentucky
Sponsor class: OTHER
First posted: 2015-04-23
Enrollment: 0
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The hypothesis of this study is that the addition of NovoTTF-100A System treatment to salvage chemotherapy will significantly increase time to treatment failure in the brain of small cell lung cancer patients.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed small cell lung cancer histology with CNS metastases
* Parenchymal disease, ten or less lesions, and supratentorial
* PS 70% or greater
* Prior CNS radiotherapy.
* No previous or currently active second malignancy
* Age \> 22 years.
* Life expectancy of ≥ 3 months.

Exclusion Criteria:

* Significant liver function impairment - AST or ALT \> 3 times the upper limit of normal; Total bilirubin \> upper limit of normal.
* Significant renal impairment (serum creatinine \> 1.7 mg/dL).
* Coagulopathy (as evidenced by PT or APTT \>1.5 times in control patients not undergoing anticoagulation).Thrombocytopenia (platelet count \< 100 x 103/μL).
* Neutropenia (absolute neutrophil count \< 1 x 103/μL).
* Anemia (Hb \< 10 g/L).
* Severe acute infection. Serious non-healing wound or ulcer on scalp
* Significant co-morbidities within 4 weeks prior to enrollment.
* Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias.
* Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts).
* Skull defect (e.g. missing bone with no replacement).
* Shunt
* Bullet fragments
* Evidence of increased intracranial pressure (midline shift \> 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness).
* Sensitivity to conductive hydrogels.
* Pregnant or lactating women

Primary outcomes:
measure: Time to treatment failure
timeFrame: Up to 3 months
Secondary outcomes:
measure: Progression Free Survival
timeFrame: Up to 6 months
measure: Overall response rate
timeFrame: Up to 2 years
measure: Duration of response
timeFrame: Up to 2 years
measure: Safety of treatment assessed by number of participants with adverse events
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky, Markey Cancer Center
state: Kentucky
Study officials:
affiliation: Lucille P. Markey Cancer Center at University of Kentucky
name: John L Villano, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01041872: Comparison of Different Propofol Formulations
Official title: Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Lidocaine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: General Anesthesia
Lead sponsor: Hopital Foch
Sponsor class: OTHER
First posted: 2010-01-01
Enrollment: 212
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate the influence of different propofol formulations(plain or with lidocaine)on anesthetic induction. Propofol plain or with lidocaine is administered using a closed-loop algorithm in order to reach a Bispectral Index target of 50.


Eligibility criteria: Inclusion Criteria:

* patients scheduled for an intravenous induction of anesthesia with propofol

Exclusion Criteria:

* Age under 18
* Pregnancy or breastfeeding
* Allergy to propofol, soya or peanuts,
* Allergy to lidocaine,
* History of central neurological disorder or brain injury,
* Patients receiving psychotropic drugs,
* Patient with a pacemaker.

Primary outcomes:
measure: necessary dose of propofol to obtain the induction of anesthesia (defined by a bispectral index of 50)
timeFrame: end of anesthetic induction
Secondary outcomes:
measure: calculated concentrations of propofol at the end of the anesthetic induction
timeFrame: end of the anesthetic induction
measure: measured plasma propofol concentrations at the end of anesthetic induction (in 20% of patients)
timeFrame: 3 months after the end of patient's recruitment
measure: pain at injection
timeFrame: during the PACU (post-anaesthesia care unit) stay
measure: heart rate and arterial pressure modifications induced by anesthetic induction
timeFrame: end of anesthetic induction
measure: patients satisfaction
timeFrame: during the PACU stay
measure: necessary dose of propofol to obtain loss of consciousness
timeFrame: end of anesthetic induction
measure: calculated concentrations of propofol at loss of consciousness
timeFrame: end of anesthetic induction
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Clinique Saint Augustin
city: Garches
country: France
facility: Laboratoire de Pharmacologie Toxicologie, hôpital Raymond Poincaré
city: Suresnes
country: France
facility: Hôpital Foch
Study officials:
affiliation: Hôpital Foch
name: Morgan LeGuen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Liu N, Chazot T, Genty A, Landais A, Restoux A, McGee K, Laloe PA, Trillat B, Barvais L, Fischler M. Titration of propofol for anesthetic induction and maintenance guided by the bispectral index: closed-loop versus manual control: a prospective, randomized, multicenter study. Anesthesiology. 2006 Apr;104(4):686-95. doi: 10.1097/00000542-200604000-00012.
Clinical trial NCT06006572: Hip DAA Closure Techniques
Official title: Direct Anterior Approach of the Hip and Variations in Wound Complications Using Different Closure Techniques
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Total Hip Replacement
Wound Complication
Lead sponsor: Rothman Institute Orthopaedics
Sponsor class: OTHER
First posted: 2023-08-23
Enrollment: 172
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to analyze the difference in rates of wound complications using two different closure techniques in Direct anterior approach for primary total hip replacement.

Detailed description: The use of the direct anterior approach (DAA) for primary total hip arthroplasty (THA) has been increasingly popular but there has been a reported increased risk of wound complications compared with a posterior approach. Wound complications can lead to increased length of stay, reoperation procedures (i.e., irrigation and debridement), patient dissatisfaction, extra visits, readmissions, increased risk of periprosthetic joint infection and overall increased costs.

Eligibility criteria: Inclusion Criteria:

* Patients older than 18 years old that will undergo THA via DAA

Exclusion Criteria:

* Previous hip arthroplasty surgeries or scars
* THA secondary to oncologic or traumatic etiologies
* BMI ≥ 40
* uncontrolled diabetes (measured by a Hgb A1c above 8)
* reported allergy to skin adhesive

Primary outcomes:
measure: Wound complications
timeFrame: 90 days
measure: Participant satisfaction
timeFrame: 90 days
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Rothman Orthopaedic Institute
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01655472: Schizophrenia Imaging
Official title: Prospective Ultrasonographic and Magnetic Resonance Imaging (MRI) Assessment of General and Brain Fetal Development in Offspring of Schizophrenic Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Foetal Differences Between Healthy and Schizophernic Parents
Keywords: schizophrenia
imaging
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-08-01
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: Schizophrenia is a common disorder with a lifetime prevalence of about 1%.Genetic studies strongly suggest a genetic component to the inheritance of schizophrenia. Structural neuroimaging studies have provided consistent evidence for brain abnormalities in schizophrenia. The timing of brain abnormalities in schizophrenia has not been determined yet.

The investigators hypothesize that brain structural changes can be detected in neonatal life. The investigators hypothesize that offspring of schizophrenic patients will have higher rates of brain structural changes in the neonatal period. The investigators propose to study early development of fetuses in offspring of patients with schizophrenia. The study is a multi-center prospective trial.


Eligibility criteria: Inclusion Criteria:

* Pregnant women who carry an offspring of a schizophrenia patient: whether the mother, the father or both suffer from schizophrenia.

Exclusion Criteria:

* Alcohol or drug abuse of pregnant woman
* Past history or present occurrence of major neurologic or somatic illness
* Genetic disease
* Other psychiatric disorders other than schizophrenia such as Mental retardation
* Bipolar Disorder and Delusional Disorder

Primary outcomes:
measure: Brain morphological changes between groups
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bat Yam
country: Israel
facility: Abarbanel Mental Health Centre
city: Beer Yaakov
country: Israel
facility: Beer Yaacov Mental health Centre
city: Hod Hasharon
country: Israel
facility: Shalvata mental health centre
city: Holon
country: Israel
facility: Edith Wolfson Medical Centre
city: Petah Tiqwa
country: Israel
facility: Geha mental health centre
city: Tel Aviv
country: Israel
facility: Brill outpatient clinic
city: Tel Aviv
country: Israel
facility: Sourasky Medical Centre
city: Tel Hashomer
country: Israel
facility: Chaim Sheba medical centre
Study officials:
affiliation: International Diabetes Federation
name: Nivi Rotenberg, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06371872: French Cohort of Patients With Rotator Cuff Lesions
Official title: French Cohort of Patients With Rotator Cuff Lesions: Changes in Shoulder Function and Quality of Life at 1, 2, 5, 8 and 10 Years, According to Their Care
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Rotator Cuff Injuries
Lead sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Sponsor class: OTHER
Collaborators: name: Euraxi Pharma
First posted: 2024-04-17
Enrollment: 519
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will consist of patients recruited during their first consultation for the management of a rotator cuff injury.

Brief summary: The purpose of this study is to identify, at 5 years, the clinical and therapeutic factors associated with improvement in shoulder functionality and quality of life in patients with transfixing (total) rotator cuff injuries undergoing treatment.

Detailed description: This is a non-interventional, prospective, longitudinal, multicentre cohort study.

The research procedure involves recruiting patients during their first consultation for the management of a rotator cuff injury. Patients will then be contacted by telephone or e-mail every year to monitor the progress of their disease and their treatment. Patients will be asked to complete self-questionnaires assessing shoulder function, quality of life and satisfaction.

Eligibility criteria: Inclusion Criteria:

* Patient, male or female, over 18 years of age.
* Patient with a transfixing (total) rotator cuff lesion confirmed by imaging.
* A patient who has been informed and has expressed no oral objection to taking part in the research.
* Patient affiliated to or benefiting from a social security scheme.

Exclusion Criteria:

* Patients over 75 years of age.
* Patients with a history of shoulder surgery.
* Patients unable to receive emails and/or answer online questionnaires.
* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.

Primary outcomes:
measure: Shoulder Pain and Disability Index
timeFrame: 5 years
measure: European quality of life scale - EQ5D
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Clinique Maussins-Nollet
Study officials:
References:
Clinical trial NCT05558072: Testicular Torsion
Official title: Is There a Toll-like 4 Receptor Relationship in Patients With Testicular Torsion?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Testicular Torsion and TLR 4 Was Investigated
Keywords: testicular torsion,
Toll-like receptors (TLR),
child
newborn
adolescent
Lead sponsor: Hisar Intercontinental Hospital
Sponsor class: OTHER
First posted: 2022-09-28
Enrollment: 64
Sex: MALE
Minimum age (years): 0
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Background:

Testicular torsion is a scrotal emergency that results in impaired blood supply to the testis and ischemia of the testis as a result of the rotation of the spermatic cord around itself. The etiology of testicular torsion is not clear, but various predisposing factors are responsible for the occurrence of testicular torsion.

Recently, with the discovery of "Toll-Like Receptors" (TLRs), new horizons have been opened in the field of innate immune system-related diseases.

Objective: To mediate the relationship between testicular torsion and TLR4 receptors.

Material-Method: Testicular specimens of patients who developed testicular ischemia after testicular torsion and underwent orchiectomy between 2012-2022 were reached. A study of TLR 4 receptors was performed in these testicular specimens. The patients were divided into two groups according to their ages newborns and adolescents.

Detailed description: Analysis of 32 newborns and 32 adolescents between the ages of 14 and 16 (mean age was 15.17 ± 0.98) testicular tissue lysate using Toll-Like Receptor antibody 4 (TLR4) ELISA (Enzyme-Linked ImmunoSorbent Assay).

Toll-like receptor 4 is a transmembrane protein that in humans is encoded by the TLR4 gene. Its activation leads to the production of inflammatory cytokines.

Eligibility criteria: Inclusion Criteria:

testicular torsion

* newborn, adolescent,

Exclusion Criteria:

* orchitis, urinary infection, trauma,

Primary outcomes:
measure: Toll-like receptor 4 positives or negative
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: